Overall, these findings suggest that leonurine regulates the ADRA1a/AMPK/SCD1 signaling axis, effectively modulating hepatic lipid metabolism in NAFLD and inhibiting lipid synthesis. This evidence concerns the gene ADRA1A and metabolic dysfunction-associated steatotic liver disease.